Methazolamide Tablet
NDC Package 42571-239-90

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Methazolamide tablets is a medication used to treat high pressure inside the eye due to certain types of glaucoma. This formulation utilizes a tablet delivery system. Marketed by Micro Labs Limited, this product is identified by NDC 42571-239 and is authorized under FDA application ANDA207438.

Identification & Billing

NDC Package Code
42571-239-90
Package Description
90 TABLET in 1 BOTTLE
Product Code
42571-239
11-Digit Billing Format
42571023990
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Methazolamide
Non-Proprietary Name
Methazolamide
Substance Name
Methazolamide
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
METHAZOLAMIDE 25 mg/1
Usage Information
This medication is used to treat high pressure inside the eye due to certain types of glaucoma. Lowering high pressure inside the eye helps to prevent blindness, vision loss, and nerve damage. Methazolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It works by decreasing the production of fluid inside the eye.

Regulatory & Marketing

Labeler Name
Micro Labs Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA207438
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-05-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (42571-239). Click a package code to view its specific billing and regulatory data.

42571-239-05
500 TABLET in 1 BOTTLE
42571-239-10
1000 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42571-239-90 identifies a specific commercial package of 90 tablet in 1 bottle of Methazolamide, a human prescription drug labeled by Micro Labs Limited. This tablet is formulated for oral use and contains methazolamide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Micro Labs Limited on March 05, 2019. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat high pressure inside the eye due to certain types of glaucoma. Lowering high pressure inside the eye helps to prevent blindness, vision loss, and nerve damage. Methazolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It works by decreasing the production of fluid inside the eye.

How is this Micro Labs Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42571023990. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42571-239-90
11-Digit CMS (5-4-2)
42571-0239-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.